These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 32505349)

  • 1. Acquired tamoxifen resistance is surmounted by GW8510 through ribonucleotide reductase M2 downregulation-mediated autophagy induction.
    Li ZN; Shu Y; Chen CG; Li XQ; Li MY; Zhao XH; Wang S; Li J
    Biochem Biophys Res Commun; 2020 Jul; 528(3):554-560. PubMed ID: 32505349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
    Chen P; Wu JN; Shu Y; Jiang HG; Zhao XH; Qian H; Chen K; Lan T; Chen CG; Li J
    Clin Sci (Lond); 2018 Jul; 132(13):1417-1433. PubMed ID: 29853661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
    Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
    Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells.
    Chen YR; Tsou B; Hu S; Ma H; Liu X; Yen Y; Ann DK
    Oncotarget; 2016 Jan; 7(2):1984-99. PubMed ID: 26675256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition.
    Shah KN; Mehta KR; Peterson D; Evangelista M; Livesey JC; Faridi JS
    Mol Cancer Res; 2014 Mar; 12(3):394-407. PubMed ID: 24362250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.
    Park JH; Ahn MY; Kim TH; Yoon S; Kang KW; Lee J; Moon HR; Jung JH; Chung HY; Kim HS
    Invest New Drugs; 2012 Oct; 30(5):1887-98. PubMed ID: 21983700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer.
    Rüstem DG; Atay S; Aydin HH; Ak H
    Anticancer Agents Med Chem; 2021 Oct; 21(16):2204-2215. PubMed ID: 33397269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance.
    Putluri N; Maity S; Kommagani R; Creighton CJ; Putluri V; Chen F; Nanda S; Bhowmik SK; Terunuma A; Dorsey T; Nardone A; Fu X; Shaw C; Sarkar TR; Schiff R; Lydon JP; O'Malley BW; Ambs S; Das GM; Michailidis G; Sreekumar A
    Neoplasia; 2014 May; 16(5):390-402. PubMed ID: 25016594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
    Li F; Miao L; Xue T; Qin H; Mondal S; Thompson PR; Coonrod SA; Liu X; Zhang X
    J Exp Clin Cancer Res; 2019 Oct; 38(1):414. PubMed ID: 31601253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer.
    Hsieh YY; Chou CJ; Lo HL; Yang PM
    Cell Death Discov; 2016; 2():16027. PubMed ID: 27551518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen.
    Chen JL; Chang CJ; Wang JY; Wen CS; Tseng LM; Chang WC; Noomhorm N; Liu HJ; Chen WS; Chiu JH; Shyr YM
    Integr Cancer Ther; 2014 May; 13(3):226-39. PubMed ID: 24525674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy.
    Wang J; Xie S; Yang J; Xiong H; Jia Y; Zhou Y; Chen Y; Ying X; Chen C; Ye C; Wang L; Zhou J
    J Hematol Oncol; 2019 Jul; 12(1):81. PubMed ID: 31340867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low GPR81 in ER
    Yu J; Du Y; Liu C; Xie Y; Yuan M; Shan M; Li N; Liu C; Wang Y; Qin J
    Life Sci; 2024 Aug; 350():122763. PubMed ID: 38823505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells.
    Qi W; Sun M; Kong X; Li Y; Wang X; Lv S; Ding X; Gao S; Cun J; Cai C; Wang X; Chen J; Yin A; Yang Q
    Oncotarget; 2016 May; 7(18):26003-15. PubMed ID: 27027343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.
    Phuong NT; Kim SK; Lim SC; Kim HS; Kim TH; Lee KY; Ahn SG; Yoon JH; Kang KW
    Breast Cancer Res Treat; 2011 Nov; 130(1):73-83. PubMed ID: 21170675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.
    Liu B; Wang T; Wang H; Zhang L; Xu F; Fang R; Li L; Cai X; Wu Y; Zhang W; Ye L
    J Hematol Oncol; 2018 Feb; 11(1):26. PubMed ID: 29471853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer.
    Tang Q; Wu L; Xu M; Yan D; Shao J; Yan S
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1368-1379. PubMed ID: 32763454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy.
    Nagelkerke A; Sieuwerts AM; Bussink J; Sweep FC; Look MP; Foekens JA; Martens JW; Span PN
    Endocr Relat Cancer; 2014 Feb; 21(1):101-12. PubMed ID: 24434718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
    Lü M; Ding K; Zhang G; Yin M; Yao G; Tian H; Lian J; Liu L; Liang M; Zhu T; Sun F
    Sci Rep; 2015 Mar; 5():8735. PubMed ID: 25736597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells.
    He M; Jin Q; Chen C; Liu Y; Ye X; Jiang Y; Ji F; Qian H; Gan D; Yue S; Zhu W; Chen T
    Oncogene; 2019 Jul; 38(28):5551-5565. PubMed ID: 30967627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.